Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free VRAYQ Stock Alerts

ViewRay (VRAYQ) Competitors

Compare

VRAYQ vs. TTOO, SDCCQ, GMVDF, AFIB, and WOK

Should you buy ViewRay stock or one of its competitors? MarketBeat compares ViewRay with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ViewRay include T2 Biosystems (TTOO), SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), Acutus Medical (AFIB), and WORK Medical Technology Group (WOK). These companies are all part of the "medical equipment" industry.

How does ViewRay compare to T2 Biosystems?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

In the previous week, T2 Biosystems had 2 more articles in the media than ViewRay. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for ViewRay. ViewRay's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Neutral

T2 Biosystems has lower revenue, but higher earnings than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

15.5% of ViewRay shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 2.5% of ViewRay shares are held by insiders. Comparatively, 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.21, meaning that its share price is 721% more volatile than the broader market.

Summary

ViewRay and T2 Biosystems tied by winning 5 of the 10 factors compared between the two stocks.

How does ViewRay compare to SmileDirectClub?

ViewRay (NASDAQ:VRAYQ) and SmileDirectClub (NASDAQ:SDCCQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

SmileDirectClub has higher revenue and earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
SmileDirectClub$470.74M0.00-$86.40M-$0.29N/A

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 0.1% of SmileDirectClub shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 64.7% of SmileDirectClub shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ViewRay has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, SmileDirectClub has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
SmileDirectClub N/A N/A N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled SmileDirectClub'saverage media sentiment score.

Company Overall Sentiment
ViewRay Neutral
SmileDirectClub Neutral

Summary

SmileDirectClub beats ViewRay on 5 of the 7 factors compared between the two stocks.

How does ViewRay compare to G Medical Innovations?

G Medical Innovations (NASDAQ:GMVDF) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

G Medical Innovations has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G Medical Innovations$4.42M0.00-$24.63MN/AN/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Company Net Margins Return on Equity Return on Assets
G Medical InnovationsN/A N/A N/A
ViewRay N/A N/A N/A

In the previous week, G Medical Innovations' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
G Medical Innovations Neutral
ViewRay Neutral

G Medical Innovations has a beta of 30.95, suggesting that its share price is 2,995% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

6.0% of G Medical Innovations shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 37.1% of G Medical Innovations shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

G Medical Innovations beats ViewRay on 3 of the 5 factors compared between the two stocks.

How does ViewRay compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
ViewRay N/A N/A N/A

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
ViewRay Neutral

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 5.2% of Acutus Medical shares are held by insiders. Comparatively, 2.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acutus Medical has higher earnings, but lower revenue than ViewRay. Acutus Medical is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Acutus Medical has a beta of 6.08, meaning that its share price is 508% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Summary

Acutus Medical and ViewRay tied by winning 5 of the 10 factors compared between the two stocks.

How does ViewRay compare to WORK Medical Technology Group?

WORK Medical Technology Group (NASDAQ:WOK) and ViewRay (NASDAQ:VRAYQ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

15.5% of ViewRay shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

WORK Medical Technology Group has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Given ViewRay's higher probable upside, analysts plainly believe ViewRay is more favorable than WORK Medical Technology Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ViewRay
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
WORK Medical Technology GroupN/A N/A N/A
ViewRay N/A N/A N/A

In the previous week, WORK Medical Technology Group's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
WORK Medical Technology Group Neutral
ViewRay Neutral

WORK Medical Technology Group has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WORK Medical Technology Group$9.81M0.00-$1.07MN/AN/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Summary

ViewRay beats WORK Medical Technology Group on 4 of the 7 factors compared between the two stocks.

Get ViewRay News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAYQ vs. The Competition

Export
MetricViewRayElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$18K$74.43M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio0.008.5021.2125.65
Price / SalesN/A193.68554.3886.31
Price / CashN/A41.3643.4956.67
Price / BookN/A7.8510.377.14
Net Income-$107.33M-$5.50M$3.57B$335.98M

ViewRay Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-99.9%$63K$7.68MN/A180
SDCCQ
SmileDirectClub
N/A$0.00
-90.0%		N/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
flat		N/AN/A$26K$4.42MN/A72
AFIB
Acutus Medical
N/A$0.00
-50.0%		N/A-99.0%$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAYQ) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel